Kodiak Sciences Inc. (KOD): Shareholders' Equity
$157.38M
As of 2025-12-31
$61.10M
As of 2026-06-30
-28.8%
3-year compound annual growth
-28.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $157.38M | +4.7% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $150.29M | -43.5% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $265.78M | -39.1% | 2026-03-31, Balance as of period end |
| 2022-12-31 | $436.17M | -34.2% | 2025-03-27, Balance as of period end |
| 2021-12-31 | $663.32M | -22.9% | 2024-03-28, Balance as of period end |
| 2020-12-31 | $860.75M | +149.2% | 2023-03-28, Balance as of period end |
| 2019-12-31 | $345.36M | +297.7% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $86.83M | n/m | 2021-03-01, Balance as of period end |
| 2017-12-31 | -$68.74M | n/m | 2020-03-16, Balance as of period end |
| 2016-12-31 | -$41.08M | n/a | 2019-03-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $157.38M | +4.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $256.59M | +18.8% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $246.94M | +245.2% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $120.87M | -21.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$207.78M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$1.01B | n/m |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $166.16M | -60.0% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $207.18M | -35.0% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $354.97M | n/m |
Compare KOD, CCCC, TSHA, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗